BIAF Stock Catalyst: bioAffinity Technologies Advances CyPath® Lung for Lung Cancer Survivor Surveillance

Sep 1, 2026 · 8:00am ET

Company progresses diagnostic tool for post-treatment monitoring.

Max move

+88.7%

High of day $8.60

Sparker timei

8:00am ET

BIAF · Sep 1, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced the advancement of its CyPath® Lung diagnostic tool for the surveillance of lung cancer survivors. The company is focusing on enhancing the tool's capabilities for post-treatment monitoring to aid in the early detection of cancer recurrence.

No specific amounts, filings, or comparators were provided in the announcement. The company has 4,416,412 shares in free float and 1,601,259 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time BIAF sparks.

Download Sniper App →

Catch the next BIAF-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →